191 related articles for article (PubMed ID: 22324425)
1. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism.
Hunfeld NG; Touw DJ; Mathot RA; van Schaik RH; Kuipers EJ
Aliment Pharmacol Ther; 2012 Apr; 35(7):810-8. PubMed ID: 22324425
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism.
Hunfeld NG; Touw DJ; Mathot RA; Mulder PG; VAN Schaik RH; Kuipers EJ; Kooiman JC; Geus WP
Aliment Pharmacol Ther; 2010 Jan; 31(1):150-9. PubMed ID: 19785625
[TBL] [Abstract][Full Text] [Related]
3. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
[TBL] [Abstract][Full Text] [Related]
4. Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype.
Sugimoto M; Shirai N; Nishino M; Kodaira C; Uotani T; Yamade M; Sahara S; Ichikawa H; Sugimoto K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2012 Oct; 36(7):627-34. PubMed ID: 22882464
[TBL] [Abstract][Full Text] [Related]
5. [Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors].
Morozov SV; Tsodikova OM; Isakov VA; Gushchin AE; Shipulin GA
Eksp Klin Gastroenterol; 2003; (6):58-63, 154. PubMed ID: 15065530
[TBL] [Abstract][Full Text] [Related]
6. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
[TBL] [Abstract][Full Text] [Related]
7. Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes.
Hayato S; Hasegawa S; Hojo S; Okawa H; Abe H; Sugisaki N; Munesue M; Horai Y; Ohnishi A
Eur J Clin Pharmacol; 2012 May; 68(5):579-88. PubMed ID: 22108775
[TBL] [Abstract][Full Text] [Related]
8. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism.
Lou HY; Chang CC; Sheu MT; Chen YC; Ho HO
Eur J Clin Pharmacol; 2009 Jan; 65(1):55-64. PubMed ID: 18751689
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
[TBL] [Abstract][Full Text] [Related]
10. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
Adachi K; Katsube T; Kawamura A; Takashima T; Yuki M; Amano K; Ishihara S; Fukuda R; Watanabe M; Kinoshita Y
Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
[TBL] [Abstract][Full Text] [Related]
11. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial.
Li ZS; Zhan XB; Xu GM; Cheng NN; Liao Z
J Gastroenterol Hepatol; 2007 Jun; 22(6):815-20. PubMed ID: 17565634
[TBL] [Abstract][Full Text] [Related]
12. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.
Hunfeld NG; Mathot RA; Touw DJ; van Schaik RH; Mulder PG; Franck PF; Kuipers EJ; Geus WP
Br J Clin Pharmacol; 2008 May; 65(5):752-60. PubMed ID: 18241283
[TBL] [Abstract][Full Text] [Related]
13. Relationship between the acid-inhibitory effects of two proton pump inhibitors and CYP2C19 genotype in Japanese subjects: a randomized two-way crossover study.
Furuta K; Adachi K; Ohara S; Morita T; Tanimura T; Koshino K; Kinoshita Y
J Int Med Res; 2010; 38(4):1473-83. PubMed ID: 20926021
[TBL] [Abstract][Full Text] [Related]
14. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.
Kagami T; Sahara S; Ichikawa H; Uotani T; Yamade M; Sugimoto M; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2016 May; 43(10):1048-59. PubMed ID: 26991399
[TBL] [Abstract][Full Text] [Related]
15. Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping.
Miehlke S; Löbe S; Madisch A; Kuhlisch E; Laass M; Grossmann D; Knoth H; Morgner A; Labenz J
Aliment Pharmacol Ther; 2011 Feb; 33(4):471-6. PubMed ID: 21175704
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection.
McNicholl AG; Linares PM; Nyssen OP; Calvet X; Gisbert JP
Aliment Pharmacol Ther; 2012 Sep; 36(5):414-25. PubMed ID: 22803691
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
[TBL] [Abstract][Full Text] [Related]
18. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects.
Warrington S; Baisley K; Boyce M; Tejura B; Morocutti A; Miller N
Aliment Pharmacol Ther; 2002 Jul; 16(7):1301-7. PubMed ID: 12144580
[TBL] [Abstract][Full Text] [Related]
19. Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers.
Nishino M; Sugimoto M; Kodaira C; Yamade M; Shirai N; Ikuma M; Tanaka T; Sugimura H; Hishida A; Furuta T
Dig Dis Sci; 2010 Jun; 55(6):1627-36. PubMed ID: 19672708
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Klotz U
Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
